CORE TITLE: Targeting Core CORE SUMMARY: Traditionally, robust protein-specific targeting ligand requirements are met by antibodies (Abs). Antibodies however often have significant problems, including high cost, selection difficulties, selectivity problems, preparation difficulties, stability and immunogenicity. The Targeting Core objective is to provide the Projects in the TCCN sets of targeting reagents for the nanoparticles that not only includes "gold standard" antibodies but novel aptamers and peptides to both endothelial, cancer and stem cells, both to specific cell surface ligands as well as the cells themselves. All projects will use the resources from the Biological Targeting Core. Specifically, the Targeting Core will develop thioaptamers and next-generation Xaptamers for targeting nanoparticles to CD44 (Project 1;
Aim 2), E-Selectin, (Project 1:
Aim 2, Project 2:
Aim 2), VGFR, EGFR, ICAM-1 and cells (Project 3:
Aim 1) and peptides and antibodies via phage display for targeting proteins (Project 1;
Aim 2) and cells (Project 3:
Aim 1; Project 4:
Aim 2). Additionally, the Targeting Core will provide conjugation of targeting ligands and all micro/nanoparticles (Projects 1-3).

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-S)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas Health Science Center Houston
United States
Zip Code
Cui, Min-Hui; Branch, Craig A; Cahill, Sean M et al. (2015) In vivo proton MR spectroscopy of pancreatic neuroendocrine tumors in a multiple endocrine neoplasia type 1 conditional knockout mouse model. Magn Reson Med 74:1221-6
Bottsford-Miller, Justin; Choi, Hyun-Jin; Dalton, Heather J et al. (2015) Differential platelet levels affect response to taxane-based therapy in ovarian cancer. Clin Cancer Res 21:602-10
Sun, Yan; Hu, Limei; Zheng, Hong et al. (2015) MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. J Pathol 235:25-36
Wen, Yunfei; Graybill, Whitney S; Previs, Rebecca A et al. (2015) Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer. Clin Cancer Res 21:448-59
Previs, Rebecca A; Coleman, Robert L; Harris, Adrian L et al. (2015) Molecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancer. Clin Cancer Res 21:955-61
Jaganathan, Hamsa; Mitra, Sucharita; Srinivasan, Srimeenakshi et al. (2014) Design and in vitro evaluation of layer by layer siRNA nanovectors targeting breast tumor initiating cells. PLoS One 9:e91986
Ozpolat, Bulent; Sood, Anil K; Lopez-Berestein, Gabriel (2014) Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev 66:110-6
Yang, Yong; Wolfram, Joy; Fang, Xiaohong et al. (2014) Polyarginine induces an antitumor immune response through binding to toll-like receptor 4. Small 10:1250-4
Tang, Lei; van de Ven, Anne L; Guo, Dongmin et al. (2014) Computational modeling of 3D tumor growth and angiogenesis for chemotherapy evaluation. PLoS One 9:e83962
Zhaorigetu, Siqin; Rodriguez-Aguayo, Cristian; Sood, Anil K et al. (2014) Delivery of negatively charged liposomes into the atherosclerotic plaque of apolipoprotein E-deficient mouse aortic tissue. J Liposome Res 24:182-90

Showing the most recent 10 out of 153 publications